Cardiovascular Events in Cancer Patients Treated with Highly or Moderately Emetogenic Chemotherapy: Results from a Population-Based Study
Table 1
Characteristics of 5827 patients with select* cancers and ≤4 cycles of HEC, MEC, or HEC/MEC combined, 2005–2007 IMPACT National Benchmark Database (OptumInsight, Eden Prairie, MN).
Characteristic
HEC and/or MEC
HEC only
MEC only
HEC/MEC combined
Total
No Aprep
Aprep
Total
No Aprep
Aprep
Total
No Aprep
Aprep
Total
No Aprep
Aprep
% Male
21.90
27.56
11.14
45.45
52.73
38.18
19.57
25.59
7.52
41.67
47.48
32.58
% Female
78.10
72.44
88.86
54.55
47.27
61.82
80.43
74.41
92.48
58.33
52.52
67.42
Mean age (yrs)
54.7
56.3
51.7
54.8
55.8
53.8
54.6
56.2
51.4
56.2
57.1
54.8
% Age ≥60
32.52
38.22
21.69
35.15
38.79
31.52
32.23
38.29
20.10
35.53
35.97
34.83
% Age ≥65
14.35
18.31
6.82
14.85
16.97
12.73
14.22
18.33
5.98
16.67
19.42
12.36
% Breast cancer
60.41
50.98
78.31
26.67
19.39
33.94
64.07
53.74
84.74
24.56
18.71
33.71
% Colorectal cancer
7.00
9.30
2.64
6.97
6.67
7.27
6.95
9.45
1.94
8.33
8.63
7.87
% Head and neck cancer
5.85
5.74
6.07
26.97
26.67
27.27
3.93
4.18
3.42
19.74
20.14
19.10
% Lung cancer
25.73
32.91
12.09
36.67
44.85
28.48
24.05
31.51
9.11
48.68
53.96
40.45
% Ovarian cancer
5.59
6.47
3.93
6.67
7.27
6.06
5.60
6.55
3.70
3.95
3.60
4.49
% Prior history of CVD‡
50.76
55.28
42.19
61.52
64.85
58.18
49.86
54.68
40.21
56.14
58.99
51.69
*
Breast, colorectal, head and neck, lung, and ovarian cancers. ‡Prior history of CVD is defined as a diagnosis of any of the following prior to the start of HEC and/or MEC: hypertension, diabetes, coronary artery disease, myocardial infarction, congestive heart failure, stroke, transient ischemic attack, deep vein thrombosis (DVT), and pulmonary embolism (PE). Note: percentage by type of cancer may add to >100% due to patients having multiple cancer types.
